JP Morgan Trims Molecular Device Rating
Analyst David Molowa says the near-term outlook is hazy for the medical-instruments maker
JP Morgan cut Molecular Device (MDCC ) to long-term buy from buy.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: